Titan Pharmaceuticals (NASDAQ:TTNP) Stock Price Passes Above 200 Day Moving Average – Time to Sell?

Titan Pharmaceuticals, Inc. (NASDAQ:TTNP) shares crossed above its 200-day moving average during trading on Friday . The stock has a 200-day moving average of $3.86 and traded as high as $4.40. Titan Pharmaceuticals shares last traded at $4.30, with a volume of 2,166 shares trading hands.

Wall Street Analyst Weigh In

Separately, Wall Street Zen initiated coverage on Titan Pharmaceuticals in a report on Tuesday, May 20th. They set a “sell” rating for the company.

Titan Pharmaceuticals Stock Performance

The business’s 50-day moving average is $4.37 and its 200-day moving average is $3.86. The company has a market capitalization of $3.91 million, a PE ratio of -0.94 and a beta of 1.30.

Titan Pharmaceuticals (NASDAQ:TTNP) last issued its earnings results on Wednesday, May 14th. The specialty pharmaceutical company reported ($0.62) earnings per share for the quarter.

Titan Pharmaceuticals Company Profile

Titan Pharmaceuticals, Inc, a pharmaceutical company, develops therapeutics for the treatment of chronic diseases in the United States and internationally. It develops products based on ProNeura, a proprietary long-term drug delivery platform. It also develops TP-2021 in combination with ProNeura technology for the treatment of chronic pruritus, a severe and debilitating condition defined as itching of the skin lasting longer than six weeks; and Nalmefene implant program for the prevention of opioid relapse following detoxification of patients suffering opioid use disorder.